Management indicated plans to provide both regulatory and clinical trial updates on blarcamesine for indications beyond Alzheimer’s, including Parkinson’s disease, Rett syndrome, and Fragile X.
European authorities have issued an updated strategy for the regulation of drugs in the EU, citing recent advances in manufacturing technology and methods as drivers for the revision. The updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results